Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target
Mirum Pharmaceuticals shares jumped 9.15% to $76.71 Friday after announcing a $68.5 million private placement with TCGX, tied to its planned Bluejay Therapeutics acquisition. Citizens raised its price target to $140, citing Mirum’s expanding rare liver disease and hepatitis delta virus pipeline.
